FEG
FBT icon

Financial Enhancement Group’s First Trust NYSE Arca Biotechnology Index Fund FBT Stock Holding History

Financial Enhancement Group’s Portfolio FBT Stock Details FBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.38M Sell
5,566
-123
-2% -$26.5K 0.16% 81
2026
Q1 		$1.19M Sell
5,689
-100
-2% -$20.7K 0.15% 85
2025
Q4 		$1.27M Sell
5,789
-31
-0.5% -$6.19K 0.17% 87
2025
Q3 		$1.09M Buy
5,820
+162
+3% +$27.6K 0.15% 87
2025
Q2 		$943K Buy
5,658
+105
+2% +$16.7K 0.13% 92
2025
Q1 		$864K Buy
5,553
+667
+14% +$116K 0.13% 84
2024
Q4 		$851K Buy
4,886
+1,189
+32% +$203K 0.13% 80
2024
Q3 		$573K Sell
3,697
-1,227
-25% -$203K 0.11% 96
2024
Q2 		$831K Buy
4,924
+26
+0.5% +$3.9K 0.13% 76
2024
Q1 		$722K Buy
4,898
+163
+3% +$24.9K 0.12% 87
2023
Q4 		$715K Buy
4,735
+755
+19% +$108K 0.13% 84
2023
Q3 		$580K Buy
3,980
+69
+2% +$10.5K 0.11% 95
2023
Q2 		$597K Buy
3,911
+214
+6% +$33.4K 0.11% 94
2023
Q1 		$573K Sell
3,697
-40
-1% -$6.28K 0.11% 96
2022
Q4 		$603K Sell
3,737
-23
-0.6% -$3.39K 0.12% 93
2022
Q3 		$496K Buy
3,760
+147
+4% +$20.6K 0.11% 78
2022
Q2 		$490K Buy
3,613
+1,745
+93% +$241K 0.11% 78
2022
Q1 		$279K Buy
1,868
+50
+3% +$7.4K 0.05% 92
2021
Q4 		$294K Buy
1,818
+187
+11% +$30.2K 0.05% 93
2021
Q3 		$271K Buy
1,631
+172
+12% +$29.4K 0.05% 86
2021
Q2 		$252K Buy
1,459
+117
+9% +$19.3K 0.05% 82
2021
Q1 		$215K Buy
1,342
+7
+0.5% +$1.2K 0.04% 86
2020
Q4 		$224K Buy
1,335
+2
+0.2% +$324 0.05% 92
2020
Q3 		$210K Sell
1,333
-20
-1% -$3.27K 0.05% 88
2020
Q2 		$227K Buy
1,353
+18
+1% +$2.83K 0.06% 89
2020
Q1 		$175K Buy
1,335
+1,313
+5,968% +$187K 0.05% 93
2019
Q4 		$3K Sell
22
-28
-56% -$3.85K ﹤0.01% 229
2019
Q3 		$6K Sell
50
-32,480
-100% -$4.32M ﹤0.01% 216
2019
Q2 		$4.58M Buy
32,530
+7,870
+32% +$1.09M 1.34% 27
2019
Q1 		$3.72M Sell
24,660
-18,873
-43% -$2.72M 1.13% 30
2018
Q4 		$6.9M Buy
43,533
+37
+0.1% +$5.06K 2.17% 13
2018
Q3 		$6.89M Buy
43,496
+2,096
+5% +$317K 2.17% 13
2018
Q2 		$5.8M Buy
+41,400
New +$5.68M 2% 17
2017
Q1 		– Sell
-51,089
Closed -$4.64M – 65
2016
Q4 		$4.64M Buy
51,089
+47,821
+1,463% +$4.48M 2.4% 14
2016
Q3 		$326K Sell
3,268
-650
-17% -$63.8K 0.18% 45
2016
Q2 		$350K Sell
3,918
-3,309
-46% -$304K 0.21% 35
2016
Q1 		$633K Sell
7,227
-182
-2% -$16K 0.41% 32
2015
Q4 		$837K Sell
7,409
-304
-4% -$32.7K 0.51% 33
2015
Q3 		$781K Sell
7,713
-22,336
-74% -$2.66M 0.51% 34
2015
Q2 		$3.73M Buy
+30,049
New +$3.63M 2.35% 13

Other funds holding FBT

First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Bessemer Group
Bessemer Group Woodbridge, New Jersey $72.7B AUM 39.36% 1-Year Est. Return
BFG
Berger Financial Group Plymouth, Minnesota $1.96B AUM 20.58% 1-Year Est. Return

Financial Enhancement Group's FBT Position: Q2 2026 in Review

Financial Enhancement Group reduced its First Trust NYSE Arca Biotechnology Index Fund (FBT) stake by 2.2% in Q2 2026, selling an estimated $26.5K and leaving 5,566 shares worth $1.38M. The position accounts for 0.16% of the portfolio, ranked #81.

Financial Enhancement Group first reported a position in FBT in Q2 2015 and has held it in 40 quarters since. The position peaked at $6.9M in Q4 2018. 339 funds tracked by Wall St. Rank hold FBT as of Q2 2026.

  • Financial Enhancement Group held 5,566 shares of First Trust NYSE Arca Biotechnology Index Fund worth $1.38M as of Q2 2026.
  • Financial Enhancement Group sold 123 First Trust NYSE Arca Biotechnology Index Fund shares in Q2 2026, an estimated $26.5K.
  • First Trust NYSE Arca Biotechnology Index Fund made up 0.16% of Financial Enhancement Group's portfolio in Q2 2026, its #81 holding.
  • Financial Enhancement Group first reported a position in First Trust NYSE Arca Biotechnology Index Fund in Q2 2015 and has held it in 40 quarters since.
  • Financial Enhancement Group's First Trust NYSE Arca Biotechnology Index Fund position peaked at $6.9M in Q4 2018.
  • 339 funds tracked by Wall St. Rank held First Trust NYSE Arca Biotechnology Index Fund as of Q2 2026.

Based on Financial Enhancement Group's 13F filing for Q2 2026, filed 7 Jul 2026.